{"id":992624,"date":"2026-08-10T07:39:13","date_gmt":"2026-08-10T11:39:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/"},"modified":"2026-08-10T07:39:13","modified_gmt":"2026-08-10T11:39:13","slug":"karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/","title":{"rendered":"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n — Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET —<\/i>\n <\/p>\n

\n NEWTON, Mass.<\/span>, Aug. 10, 2026<\/span> \/PRNewswire\/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm’s management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates.<\/p>\n

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under “Events & Presentations” in the Investor section of the Company’s website, http:\/\/investors.karyopharm.com\/events-presentations<\/a>. An archived webcast will be available on the Company’s website approximately two hours after the event.<\/p>\n

\n About Karyopharm Therapeutics<\/b>\n <\/p>\n

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company’s lead therapy, XPOVIO\u00ae<\/sup> (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO\u00ae in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor’s potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information about our people, science and pipeline, please visit www.karyopharm.com<\/a>, and follow us on LinkedIn<\/a>\u00a0and on X at @Karyopharm.<\/p>\n

XPOVIO\u00ae<\/sup> and NEXPOVIO\u00ae<\/sup> are registered trademarks of Karyopharm Therapeutics Inc.<\/p>\n

\n

\n \"\"\n <\/p>\n<\/p><\/div>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026-302845213.html<\/a><\/p>\n

SOURCE Karyopharm Therapeutics Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire — Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET — NEWTON, Mass., Aug. 10, 2026 \/PRNewswire\/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm’s management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, … <\/p>\n

Continue reading “Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-992624","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKaryopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire — Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET — NEWTON, Mass., Aug. 10, 2026 \/PRNewswire\/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm’s management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, … Continue reading "Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T11:39:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS617852\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026\",\"datePublished\":\"2026-08-10T11:39:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/\"},\"wordCount\":340,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS617852\\\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/\",\"name\":\"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS617852\\\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476\",\"datePublished\":\"2026-08-10T11:39:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS617852\\\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS617852\\\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/","og_locale":"en_US","og_type":"article","og_title":"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Market Newsdesk","og_description":"PR Newswire — Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET — NEWTON, Mass., Aug. 10, 2026 \/PRNewswire\/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm’s management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, … Continue reading \"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-10T11:39:13+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS617852\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026","datePublished":"2026-08-10T11:39:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/"},"wordCount":340,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS617852\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/","name":"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS617852\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476","datePublished":"2026-08-10T11:39:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS617852\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS617852\/Karyopharm-Therapeutics-Logo.jpg?id=OA2833476"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=992624"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/992624\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=992624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=992624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=992624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}